Phase I/II Clinical Study of TAS0313 in Patients with Solid Tumor

Taiho Pharmaceutical Co., Ltd.0 个研究点目标入组 130 人开始时间: 2018年1月11日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Provided written informed consent for participate in clinical trial
•2. Has histologically or cytologically confirmed solid tumor(s) for which standard therapy has been performed
•3. Has been confirmed to have any of the following genotypes by human leukocyte antigen (HLA) genotyping test: HLA-A*02:01, -A*02:06, -A*02:07, -A*11:01, -A*24:02, -A*31:01, and -A*33:03
•4. Has a history of two or less chemotherapy regimens and meets any of the following (Cohort C1).
•a) Received standard therapy including a platinum drug for unresectable locally advanced or metastatic urothelial carcinoma.
•b) Received standard pre/post-operative adjuvant therapy including a platinum drug for localized muscle-invasive urothelial carcinoma, which was confirmed to recur or progress within 12 months after the end of the therapy.
•5. Has demonstrated disease progression after pembrolizumab for unresectable locally advanced or metastatic urothelial carcinoma (Cohort C2).

•1. Has serious diseases or conditions
•2. Has a history of hypersensitivity to drugs in classes related to TAS0313, any excipient of TAS0313
•3. Pregnant or lactating women or women of child-bearing potential who have a positive pregnancy test (urine or serum) within seven days prior to enrollment
•4. Has received prior therapy with immunotherapy agents (Cohort C1)
•5. Has received prior therapy with immunotherapy agents and was discontinued from that treatment due to irAE (Cohort C2)

发起方